Table 1.
Clinicopathological characteristics.
| Characteristics | No. (%) | Median Survival, mo | p-Value, Log-Rank Test |
|---|---|---|---|
| Age | |||
| ≤70 years | 36 (45.6%) | 2.0 | 0.514 |
| >70 years | 43 (54.4%) | 2.0 | |
| Sex | |||
| Female | 53 (67.1%) | 2.0 | 0.484 |
| Male | 26 (32.9%) | 3.0 | |
| Tumour dimensions | |||
| ≤60 mm | 32 (40.5%) | 2.0 | 0.511 |
| >60 mm | 34 (43%) | 2.0 | |
| NA | 13 (16.5%) | ||
| Stage at diagnosis | |||
| IVA | 5 (6.3%) | 9.0 | |
| IVB | 24 (30.4%) | 2.0 | 0.031 |
| IVC | 48 (60.8%) | 2.0 | |
| NA | 2 (2.5%) | ||
| Leukocytosis | |||
| <10,000/mm3 | 12 (15.2%) | 1.0 | |
| 10,000–20,000/mm3 | 44 (55.7%) | 2.5 | 0.003 |
| 20,000–30,000/mm3 | 12 (15.2%) | 1.0 | |
| >30,000/mm3 | 4 (5.1%) | 1.0 | |
| NA | 7 (8.9%) | ||
| Diagnosis | |||
| Cytology | 36 (45.6%) | 1.0 | 0.001 |
| Histology | 43 (54.4%) | 2.0 | |
| Compressive symptoms | |||
| Yes | 68 (86.1%) | 1.0 | 0.451 |
| No | 9 (11.4%) | 2.0 | |
| NA | 9 (11.4%) | ||
| Previous or coexistent WDTC | |||
| Yes | 9 (11.4%) | 5.0 | 0.004 |
| No | 63 (79.7%) | 2.0 | |
| NA | 7 (8.9%) | ||
| Therapeutic approach | |||
| Only symptomatic | 31 (39.2%) | <1.0 | |
| Only surgery | 11 (13.9%) | 2.0 | |
| Only RT | 11 (13.9%) | 2.5 | |
| Only CT | 2 (2.5%) | 0.5 | <0.001 |
| Only TKI | 3 (3.8%) | 3.0 | |
| S + RT + CT | 6 (7.6%) | 38.5 | |
| S + RT | 9 (11.4%) | 5.0 | |
| S + CT | 4 (5.0%) | 6.0 | |
| S + RT + CT + TKI | 2 (2.5%) | 8.0 | |
| S + TKI | 1 (1.3%) | 9.0 |
NA, not available; CT, chemotherapy; RT, radiotherapy; S, surgery; TKI, tyrosine kinase inhibitors; WDTC, well-differentiated thyroid cancer.